Κατάλυση κολπικής μαρμαρυγής στην καρδιακή ανεπάρκεια

Atrial fibrillation (AF) ablation requires the creation of continuous, transmural, and permanent lesions while simultaneously minimizing the risk of complications. The Medtronic Affera™ system, combined with the Sphere-9™ catheter, constitutes an integrated platform that addresses these challenges. By unifying high-definition three-dimensional electroanatomical mapping (HD Mapping) and on-demand dual-energy delivery (RF and PFA), the system offers distinct advantages in the daily clinical practice of electrophysiologists.

1. Dual-Energy Platform Flexibility

The primary technical advantage of the system is the integration of radiofrequency (RF) current and pulsed field ablation (PFA) within the same generator and catheter.

  • Selective Myocardial Ablation (PFA): Via non-thermal irreversible electroporation, myocardial cells are targeted, thereby protecting tissues with higher sensitivity thresholds, such as nerves and vessels.
  • Focal Thermal Ablation (RF): Remains immediately available for anatomical regions where geometry or tissue thickness requires thermal diffusion to achieve a permanent conduction block.
  • Dynamic Switching: The interventional cardiologist can transition from one energy modality to the other within seconds without exchanging tools, depending on the real-time anatomical requirements.

2. Workflow Efficiency Optimization

The "all-in-one" architecture of the system eliminates the need for multiple specialized catheters, offering significant operational efficiency:

  • Single-Catheter Solution: The Sphere-9™ catheter performs both ultra-high-density mapping (pre- and post-ablation) and lesion delivery.
  • Low Catheter Profile (8 Fr) vs. Competitors: In contrast to most competitive single-shot PFA platforms that require large, rigid introducer sheaths, the Sphere-9™ catheter features an 8 French shaft and is compatible with a standard 8.5 French steerable sheath.
  • Single Transseptal Access: Only a single transseptal puncture and one steerable sheath are required, reducing preparation time and the probability of complications at the venous access site.
  • Significant Time Reduction: Total procedural time and fluoroscopy exposure time are minimized.

3. Sphere-9™ Catheter Geometry and Lesion Quality

The design of the catheter differs from conventional focal catheters or fixed-shape (circular/flower-shaped) catheters:

  • Spherical Lattice Tip: The compliant 9mm lattice tip easily conforms to the anatomical intricacies of the atrium, ensuring stable and expanded tissue contact.
  • Broader Lesion Footprint: Due to the size of the tip, broader and more homogeneous isolation lines are created compared to conventional 4mm RF catheters, reducing the likelihood of conduction gaps.
  • HD Electrograms: The 9 integrated low-noise microelectrodes allow accurate recording of local electrograms (EGMs), providing immediate confirmation of isolation.

4. Anatomically Validated Safety Profile

The delivery of PFA energy via the Affera™ system eliminates the most severe complications associated with the thermal diffusion of older modalities:

  • Elimination of Esophageal Injury Risk: Avoiding thermal energy on the posterior walls of the left atrium minimizes the probability of atrio-esophageal fistula formation.
  • Prevention of Pulmonary Vein Stenosis (PV Stenosis): Since PFA does not affect the vascular collagen structure, PV isolation can be performed with greater safety closer to the ostium, if required.
  • Phrenic Nerve Protection: The risk of permanent phrenic nerve injury during right pulmonary vein ablation is dramatically reduced.
  • Reduction of Thromboembolic Events: Continuous irrigation of the lattice tip prevents blood overheating and charring formation.

5. Clinical Efficacy in Challenging Anatomical Lines

Beyond standard pulmonary vein isolation (PVI), the system excels in creating supplementary ablation lines, which are essential for patients with persistent AF:

  • Roof Line & Mitral Isthmus: The flexibility of the catheter allows stable contact in challenging anatomical angles.
  • Permanent Conduction Block: Clinical data (such as from the SPHERE Per-AF study[1]) confirm that lesion creation via the Affera™ platform ensures high rates of long-term freedom from atrial tachyarrhythmias, due to the exceptional durability of the transmural lesions.

Conclusion

For the modern cardiologist and electrophysiologist, the advantages of the Medtronic Affera™ system are summarized in the safety of non-thermal energy, the flexibility of the dual platform (RF/PFA), and the speed of a unified workflow (HD Mapping & Ablation). This technological convergence optimizes clinical outcomes while simultaneously reducing laboratory complexity.

References

  1. Anter E, Mansour M, Nair DG, Sharma D, Taigen TL, Neuzil P, Kiehl EL, Kautzner J, Osorio J, Mountantonakis S, Natale A, Hummel JD, Amin AK, Siddiqui UR, Harlev D, Hultz P, Liu S, Onal B, Tarakji KG, Reddy VY; SPHERE PER-AF Investigators. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med. 2024 Aug;30(8):2303-2310. doi: 10.1038/s41591-024-03022-6. Epub 2024 May 17. PMID: 38760584; PMCID: PMC11333282.

References

  1. Anter E, Mansour M, Nair DG, Sharma D, Taigen TL, Neuzil P, Kiehl EL, Kautzner J, Osorio J, Mountantonakis S, Natale A, Hummel JD, Amin AK, Siddiqui UR, Harlev D, Hultz P, Liu S, Onal B, Tarakji KG, Reddy VY; SPHERE PER-AF Investigators. Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial. Nat Med. 2024 Aug;30(8):2303-2310. doi: 10.1038/s41591-024-03022-6. Epub 2024 May 17. PMID: 38760584; PMCID: PMC11333282.
2026-11-18T22:49:03+00:00